Canbridge Pharmaceuticals (FRA:MF1) Tariff Resilience Score: 0/10 (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MF1 Canbridge Pharmaceuticals Inc FRA:MF1
48 GF Score
Price €0.17
GF Value €0.03
! 7 Warning Signs
View Full Analysis

What is Canbridge Pharmaceuticals Tariff Resilience Score?

Canbridge Pharmaceuticals has the Tariff Resilience Score of 0, which implies that the company might have .

Canbridge Pharmaceuticals has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Canbridge Pharmaceuticals might have .

Canbridge Pharmaceuticals  (FRA:MF1) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Canbridge Pharmaceuticals Tariff Resilience Score Related Terms

FRA:MF1
48GF Score
Canbridge Pharmaceuticals Inc FRA:MF1
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Canbridge Pharmaceuticals (FRA:MF1) Overvalued in 2026?

Based on GuruFocus' analysis, Canbridge Pharmaceuticals stock appears to be overvalued. The current stock price of €0.17 is trading 473.3% above its estimated GF Value™ of €0.03.

Key valuation signals for FRA:MF1:

  • Tariff Resilience Score: 0
  • GF Value™: €0.03 vs. price of €0.17 (473.3% above fair value)
  • GF Score™: 48/100 with 7 warning signs

No single metric tells the full story. See the FRA:MF1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Canbridge Pharmaceuticals Business Description

Other Exchanges 01228:Hong Kong
Address No. 388 Xinping Street, Unit 9, 10th Floor, Building 21, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
48GF Score

Get the complete analysis for FRA:MF1

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.17
Price
€0.03
GF Value